Press Releases Gilead Sciences, Inc.

Equities

GILD

US3755581036

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 21:00:00 23/04/2025 BST			5-day change	1st Jan Change
106.38 ^USD	+0.82%		-0.11%	+15.17%

04-23	TD Cowen Adjusts Gilead Sciences Price Target to $110 From $100, Maintains Buy Rating	MT
04-21	Gilead Says Trodelvy-Keytruda Combination Improved Progression-Free Survival in Breast Cancer Study	MT

Press Releases

Gilead Sciences - Trodelvy Plus Keytruda Demonstrates a Statistically Significant and Clinically Meaningful Improvement in Progression Free Survival in Patients with Previously Untreated PD-L1+ Metastatic Triple-Negative Breast Cancer	04-22	AQ
Biomedical HIV Prevention Summit in Atlanta Is the Focus To Drive Meaningful Action With Gilead Sciences	04-22	AQ
Trodelvy® Plus Keytruda® Demonstrates a Statistically Significant and Clinically Meaningful Improvement in Progression Free Survival in Patients With Previously Untreated PD-L1+ Metastatic Triple-Negative Breast Cancer	04-21	BU
Gilead Sciences: Advancing Oncology Care Through Gilead's Research Scholars Program	04-15	AQ
Gilead Sciences : First Quarter 2025 Estimated Acquired IPR&D	04-10	PU
Gilead Sciences to Release First Quarter 2025 Financial Results on Thursday, April 24, 2025	04-10	BU
PatientView Ranks Gilead "Best" at ESG	04-10	AQ
Gilead Sciences: The Global Health Challenge of HIV and Hepatitis B Coinfections	04-08	AQ
Discovering a Breakthrough: Gilead's Long-Standing Commitment to Helping Change the Course of HIV	04-01	AQ
Gilead Sciences: Using Lessons From the HIV Epidemic To Help Reduce Stigma Around Lung Cancer	03-25	AQ
Gilead Sciences Ranked in Top Five Most JUST List for Biopharma Companies	03-18	AQ
Gilead Sciences - Women's History Month Celebrated With Its Team	03-14	AQ
First Clinical Data for Gilead's Investigational Once-Yearly Lenacapavir for HIV Prevention Presented at CROI 2025 and Published in The Lancet	03-12	AQ
Gilead Presents New HIV Treatment and Cure Research Data at CROI 2025, Including an Investigational Long-Acting, Twice-Yearly Therapy Option	03-12	BU
First Clinical Data for Gilead’s Investigational Once-Yearly Lenacapavir for HIV Prevention Presented at CROI 2025 and Published in The Lancet	03-11	BU
European Medicines Agency Validates Gilead’s Marketing Authorization Application and EU-Medicines for All Application for Twice-Yearly Lenacapavir for HIV Prevention	02-24	BU
Gilead’s Seladelpar Granted Conditional European Marketing Authorization for the Treatment of Primary Biliary Cholangitis	02-20	BU
Gilead Sciences to Present at Upcoming Investor Conferences	02-19	BU
The Centrifuge Sessions: How Gilead Sciences Is Impacting Autoimmune Disease	02-19	AQ
U.S. FDA Accepts Gilead’s New Drug Applications for Twice-Yearly Lenacapavir for HIV Prevention Under Priority Review	02-18	BU
IDEAYA Announces Further Gilead Sciences Clinical Study Collaboration Evaluating Combination of Trodelvy and IDE397 in MTAP-Deletion NSCLC	02-14	AQ
Gilead Sciences : Fourth Quarter 2024 Resource Book	02-11	PU
Gilead Sciences : Fourth Quarter 2024 Prepared Remarks	02-11	PU
Gilead Sciences : Fourth Quarter 2024 Summary of Remarks	02-11	PU
Gilead Sciences : Fourth Quarter 2024 Supplementary Information	02-11	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Gilead Sciences, Inc.

Equities

GILD

US3755581036

Pharmaceuticals

Press Releases

Filters